Cyclacel gains space for sapacitabine as it tweaks Daiichi Sankyo agreement
This article was originally published in Scrip
Cyclacel has secured an amendment to its in-licensing agreement with Daiichi Sankyo for sapacitabine in a move that takes the pressure off the US venture to get a first approval for its lead product by this September.
You may also be interested in...
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.